Eli Lilly and Company

About

Eli Lilly and Company is a global pharmaceutical company listed on the New York Stock Exchange (LLY). It is included here as a major industry player whose recent portfolio and partnerships intersect with aging biology rather than as a dedicated longevity company. Its incretin franchise, the GIP/GLP-1 receptor agonist tirzepatide (Mounjaro and Zepbound), targets type 2 diabetes and obesity and is under wide study for cardiometabolic and other age-related outcomes, and its anti-amyloid antibody donanemab (Kisunla) is approved for early Alzheimer's disease. In 2025-2026 Lilly entered a research collaboration and then a global R&D and licensing agreement with the AI drug-discovery company Insilico Medicine, and it was a cornerstone investor in Insilico's Hong Kong listing. The company runs early-stage discovery efforts, including its Gateway Labs incubators, across metabolic, neurodegenerative and immunological disease.

Rating breakdown

Aggregate 42/100 · rank #8 in the commercial table full ratings →

Expand a signal to see what contributes to it.

Key outputs

• product Tirzepatide (Mounjaro / Zepbound): GIP/GLP-1 receptor agonist for type 2 diabetes and obesity, studied for cardiometabolic and age-related outcomes ↗ 2022
• product Donanemab (Kisunla): anti-amyloid antibody approved for early symptomatic Alzheimer's disease ↗ 2024
• other Global R&D and licensing collaboration with Insilico Medicine for AI-discovered drugs (approx. US$2.75B total deal value); prior 2025 research collaboration; IPO cornerstone investor ↗ 2026
• publication Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1, NEJM): substantial, sustained weight loss in adults with obesity, underpinning study of the incretin franchise in age-related cardiometabolic disease ↗ 2022
• publication Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial (JAMA): amyloid-clearing antibody slowed clinical decline in early Alzheimer's disease, the pivotal trial supporting Kisunla approval ↗ 2023

Registered clinical trials

100 trials list this organisation as lead sponsor ClinicalTrials.gov ↗

• A Study of Abemaciclib (LY2835219) in Healthy Participants ↗ PHASE1 · RECRUITING · 2026-09-02
• A Study of LY4268989 (MORF 057) in Healthy Participants ↗ PHASE1 · RECRUITING · 2026-07-20
• A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7) ↗ PHASE2 · RECRUITING · 2026-05-20
• Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis ↗ NA · RECRUITING · 2026-03-09
• A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes ↗ PHASE3 · RECRUITING · 2026-02-06
• A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight ↗ PHASE3 · ACTIVE_NOT_RECRUITING · 2026-01-24
• A Study of LY4064809 in Healthy Adult Participants ↗ PHASE1 · COMPLETED · 2026-01-12
• A Study of LY4064809 in Healthy Adult Chinese Participants ↗ PHASE1 · COMPLETED · 2025-10-24

Showing 8 of 100 registered trials.

Financial

Market cap

USD 1050.00B · LLY (2026-09-29)

Recent deals & partnerships

Headline values are potential totals (mostly contingent milestones), not cash received.

Key people

Research fields

Links